Treatment of chronic hepatitis B: Focus on telbivudine

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 3, 2009, Pages 259-268

  Lui, Yanni Y N ^a   Chan, Henry L Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adefovir dipivoxill; Efficacy; Entecavir; Hepatitis B; Interferon; Lamivudine; Pharmacokinetics; Resistance; Safety; Telivudine; Tenofovir; Treatment

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CLEVUDINE; EMTRICITABINE; ENTECAVIR; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; NUCLEOSIDE; PYRIMIDINONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DNA SYNTHESIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBRYOTOXICITY; GEOGRAPHIC DISTRIBUTION; HEART ARRHYTHMIA; HEPATITIS B; HUMAN; INCIDENCE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PERIPHERAL NEUROPATHY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; DRUG ANTAGONISM; DRUG EFFECT; HEPATITIS B VIRUS; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES; VIRUS REPLICATION;

EID: 67649088400     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.6     Document Type: Review

References (65)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 34(6), 1225-1241 (2001).
2. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2, 263-283 (2008).
3. Chan HLY, Sung JJY. Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis. 26(2), 153-161 (2006).
4. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol. Clin. North Am. 23(3), 437-455 (1994).
5. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
6. Chen G, Lin W, Shen F et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 101(8), 1797-1803 (2006).
7. Chan HLY, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J. Clin. Oncol. 26(2), 177-182 (2008).
8. 4 copies/ml is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B patients: an update from the R.E.V.E.A.L.-HBV study. Hepatology 46(Suppl. 1), 640A (2007).
9. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3), 678-686 (2006).
10. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351 (15), 1521-1531 (2004).
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45(2), 507-539 (2007).
12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50(2), 227-242 (2009).
13. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendation. Hepatology 39(3), 857-861 (2004).
14. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682-2695 (2005).
15. Chan HL, Leung NW, Hui AY et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann. Intern. Med. 142(4), 240-250 (2005).
16. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454), 123-129 (2005).
17. Chan HL, Hui AY, Wong VW et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 41(6), 1357-1364 (2005).
18. 67 (2008).
19. Marcellin P, Piratvisuth T, Brunetto M et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatotos B treated with peginterferon α-2a (4oKD) with or without lamivudine: results of 4-year follow-up. J. Hepatol. 48(Suppl. 2), S46 (2008).
20. Marcellin P, Lau GK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. EnglJ. Med. 351(12), 1206-1217 (2004).
21. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131(6), 1734-1751 (2006).
22. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chornic hepatitis B. N. Engl. J. Med. 354(10), 1001-1010 (2006).
23. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354(10), 1011-1020 (2006).
24. Bryant ML, Bridges EG, Placidi L et al. Antiviral L- nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45(1), 229-235 (2001).
25. Standring DN, Bridges EG, Placidi L et al. Antiviral β- L-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. 12(Suppl. 1), 119-129 (2001).
26. Zhou XJ, Lim SG, Lloyd DM et al. Pharmacokinetics of telbivudine following administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacokinetic implications. Antimicrob. Agents Chemother. 50(3), 874-879 (2006).
27. Zhou XJ, Lloyd DM, Chao GC et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J. Clin. Pharmacol. 46(3), 275-281 (2006).
28. Hu P, Jiang J, Wang H et al. Single-dose and multiple-dose pharmacokinetics and safety oftelbivudine after oral administration in healthy Chinese subjects. J. Clin. Pharmacol. 46(9), 999-1007 (2006).
29. Zhou XJ, Marbury TC, Alcorn HW et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob. Agents Chemother. 50(5), 1721-1726 (2006).
30. Zhou XJ, Swan S, Smith WB et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob. Agents Chemother. 51(12), 4231-4235 (2007).
31. Zhou XJ, Fielman BA, Lloyd DM et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob. Agents Chemother. 50(7), 2309-2315 (2006).
32. Zhou XJ, Pietropaolo K, Becker M et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir. Gastroenterology 132(Suppl. 2), A766 (2007).
33. Zhou XJ, Fielman B, Dubuc-Patrick G et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon α-2a or cyclosporine in healthy subjects. J. Hepatol. 44(Suppl. 2), S194 (2006).
34. Bridges EG. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. J. Hepatol. 44(Suppl. 2), S147 (2006).
35. Lai CL, Lim SG, Brown NA et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40(3), 719-726 (2004).
36. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2), 528-536 (2005).
37. Lai CL, Leung N, Teo EK et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs lamivudine vs combination treatment in hepatitis B patients: two-year results. Gastroenterology 128(Suppl. 2), A692 (2005).
38. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chornic hepatitis B. N. Engl. J. Med. 357(25), 2576-2588 (2007).
39. Lai CL, Gane E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Hepatology 44(Suppl. 1), A222 (2006).
40. Di Bisceglie AM, Lai CL, Gane E et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nudeoside-treated hepatitis B patients. Hepatology 44(Suppl. l), 230A (2006).
41. Gane EJ, Wong Y, Buti M et al. Continued telbivudine treatment results in high rates of maintained response in HBeAg-postivie patients at 3 years. Hepatology 48(Suppl. 1), 729A (2008).
42. Hou J, Yin YK, Xu D et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47(2), 447-454 (2008).
43. Safadi R, Xie Q, Chen Y et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24. J. Hepatol. 46(Suppl. 1), S196-S197 (2007).
44. Chan HLY, Heathcote EJ, Marcellin P et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med. 147(11), 745-754 (2007).
45. Chan HLY, Wang H, Niu J et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir. Ther. 12(3), 345-353 (2007).
46. Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19(11), 1276-1282 (2004).
47. Ding C, Wong VWS, Chow K et al. Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy. Antivir. Ther. 11(8), 1041-1049 (2006).
48. Brown CA, Smithz F, Laessig KA et al. Creatine kinase (CK) elevations and muscle toxicities associated with chronic telbivudine (LOT) use in prospective clinical trials, Hepatology 46(Suppl. 1), 655A (2007).
49. Zhang XS, Jin R, Zhang SB et al. Clinical features of adverse reactions associated with telbivudine. World J. Gastroenterol. 14(22), 3549-3553 (2008).
50. Heathcote E, Gane EJ, deMan RA et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 48(Suppl. 1), 376A (2008).
51. Marcellin P, Buti M, Krastev Z et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology 48(Suppl. 1), 370A (2008).
52. Suh DJ, Herrmann E, Zeuzem S et al. Head-to-head comparison of viral kinetics of telbivudine and entecavir in patients with chronic hepatitis B over the first 12 weeks of treatment. Hepatology 48(SuppI. 1), 191A (2008).
53. Tenney DJ, Pokornowski KA, Rose RE et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol. Int. 2, A88 (2008).
54. Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol. Int. 2(3), 284-295 (2008).
55. Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 5(8), 890-897 (2007).
56. van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52(3), 420-424 (2003).
57. Chan HLY, Wong ML, Hui AY et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J. Gastroenterol. 902), 2695-2697 (2003).
58. Chan HLY, Wong VWS, Tse AML et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol. 5(12), 1462-1468 (2007).
59. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl.J. Med. 348(9), 808-816 (2003).
60. Hadziyannis SJ, Tassopouios NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348(9), 800-807 (2003).
61. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dioivoxiol for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology 44(Suppl. 1), 548A (2006).
62. Heathcote J, George J, Gordon S et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J. Hepatol. 48(Suppl. 2), S32 (2008).
63. Marcellin P, Jacobson I, Halbersetzer F et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J. Hepatol. 48(Suppl. 2), S26 (2008).
64. Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133(5), 1437-1444 (2007).
65. Shouval D, Akarca U, Hatzis G et al. Continues virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg-chronic hepatitis B patients (study ETV-027). J. Hepatol. 130(Suppl. 1), S21-S22 (2006).